Buprenorphine/naloxone - Ology Bioservices

Drug Profile

Buprenorphine/naloxone - Ology Bioservices

Alternative Names: NanoBUP; NTC-0510; NTC-510

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nanotherapeutics
  • Developer Nanotherapeutics; Ology Bioservices
  • Class Antidotes; Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Dental pain
  • Discontinued Opioid abuse

Most Recent Events

  • 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
  • 12 May 2016 Discontinued - Phase-I for Opioid abuse in USA (PO)
  • 12 May 2016 Planned Prescription Drug User Fee Act (PDUFA) date for Opioid abuse (In volunteers) in USA (PO) is 2016-05-12
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top